Novartis entered a global collaboration with Arrowhead Pharmaceuticals, investing $200 million upfront to develop ARO-SNCA, an siRNA-based therapy targeting alpha-synuclein for synucleinopathies including Parkinson’s disease. Leveraging Arrowhead’s Targeted RNAi Molecule platform that enables subcutaneous delivery across the blood-brain barrier, the partnership aims to advance preclinical and discovery-stage programs for neurodegenerative diseases. This deal underscores the increasing interest in RNAi therapeutics for central nervous system disorders.